Notwithstanding positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from managed care entities. The insurers are frequently erecting limitations to access, including steep cost restrictions and approval processes that restrict patient availabil… Read More